Zihao Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zihao Tang has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Chenyu Wang
University of Sydney
3 shared publicationsMariano Cabezas
Brain and Mind Centre, University of Sydney, Sydney, Australia
3 shared publications- Mariano Cabezas
Macquarie University Hearing Macquarie University Sydney NSW Australia
3 shared publications - Michael Barnett
Brain and Mind Centre, University of Sydney, Sydney, Australia
3 shared publications - Chenyu Wang
Brain and Mind Centre The University of Sydney Sydney New South Wales Australia
2 shared publications Dongnan Liu
University of Sydney
2 shared publications
Latest Publications
- Open Access
- 3 December 2024
- Published by Association for Computing Machinery (ACM)
- p. 1
Fibre Population-guided Pre-training for 3D Spatial Super-Resolution on Multimodal Brain Diffusion MR Imaging
- 3 December 2024
- Published by Association for Computing Machinery (ACM)
- p. 1
Open AccessFibre Population-guided Pre-training for 3D Spatial Super-Resolution on Multimodal Brain Diffusion MR Imaging
- Open Access
- 19 October 2023
- Published by Springer Nature in npj Digital Medicine
- Vol. 6 (1) , 1-9
A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis
Modern management of MS targets No Evidence of Disease Activity (NEDA): no clinical relapses, no magnetic resonance imaging (MRI) disease activity and no disability worsening. While MRI is the principal tool available to neurologists for monitoring clinically silent MS disease activity and, where appropriate, escalating treatment, standard radiology reports are qualitative and may be insensitive to the development of new or enlarging lesions. Existing quantitative neuroimaging tools lack adequate clinical validation. In 397 multi-center MRI scan pairs acquired in routine practice, we demonstrate superior case-level sensitivity of a clinically integrated AI-based tool over standard radiology reports (93.3% vs 58.3%), relative to a consensus ground truth, with minimal loss of specificity. We also demonstrate equivalence of the AI-tool with a core clinical trial imaging lab for lesion activity and quantitative brain volumetric measures, including percentage brain volume loss (PBVC), an accepted biomarker of neurodegeneration in MS (mean PBVC −0.32% vs −0.36%, respectively), whereas even severe atrophy (>0.8% loss) was not appreciated in radiology reports. Finally, the AI-tool additionally embeds a clinically meaningful, experiential comparator that returns a relevant MS patient centile for lesion burden, revealing, in our cohort, inconsistencies in qualitative descriptors used in radiology reports. AI-based image quantitation enhances the accuracy of, and value-adds to, qualitative radiology reporting. Scaled deployment of these tools will open a path to precision management for patients with MS.
- 19 October 2023
- Published by Springer Nature in npj Digital Medicine
- Vol. 6 (1) , 1-9
Open AccessA real-world clinical validation for AI-based MRI monitoring in multiple sclerosis
Modern management of MS targets No Evidence of Disease Activity (NEDA): no clinical relapses, no magnetic resonance imaging (MRI) disease activity and no disability worsening. While MRI is the principal tool available to neurologists for monitoring clinically silent MS disease activity and, where appropriate, escalating treatment, standard radiology reports are qualitative and may be insensitive to the development of new or enlarging lesions. Existing quantitative neuroimaging tools lack adequate clinical validation. In 397 multi-center MRI scan pairs acquired in routine practice, we demonstrate superior case-level sensitivity of a clinically integrated AI-based tool over standard radiology reports (93.3% vs 58.3%), relative to a consensus ground truth, with minimal loss of specificity. We also demonstrate equivalence of the AI-tool with a core clinical trial imaging lab for lesion activity and quantitative brain volumetric measures, including percentage brain volume loss (PBVC), an accepted biomarker of neurodegeneration in MS (mean PBVC −0.32% vs −0.36%, respectively), whereas even severe atrophy (>0.8% loss) was not appreciated in radiology reports. Finally, the AI-tool additionally embeds a clinically meaningful, experiential comparator that returns a relevant MS patient centile for lesion burden, revealing, in our cohort, inconsistencies in qualitative descriptors used in radiology reports. AI-based image quantitation enhances the accuracy of, and value-adds to, qualitative radiology reporting. Scaled deployment of these tools will open a path to precision management for patients with MS.
- Open Access
- 28 July 2023
- Published by Elsevier in NeuroImage: Clinical
- Vol. 39, 103483
Validation of deep learning techniques for quality augmentation in diffusion MRI for clinical studies
- 28 July 2023
- Published by Elsevier in NeuroImage: Clinical
- Vol. 39, 103483
Open AccessValidation of deep learning techniques for quality augmentation in diffusion MRI for clinical studies
- 1 December 2022
- Published by Springer Nature
- p. 65-76
Diffusion MRI Fibre Orientation Distribution Inpainting
- 1 December 2022
- Published by Springer Nature
- p. 65-76
Diffusion MRI Fibre Orientation Distribution Inpainting
- 16 February 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. 26 (6) , 2680-2692
Multiple Sclerosis Lesion Analysis in Brain Magnetic Resonance Images: Techniques and Clinical Applications
Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system, characterized by the appearance of focal lesions in the white and gray matter that topographically correlate with an individual patient’s neurological symptoms and signs. Magnetic resonance imaging (MRI) provides detailed in-vivo structural information, permitting the quantification and categorization of MS lesions that critically inform disease management. Traditionally, MS lesions have been manually annotated on 2D MRI slices, a process that is inefficient and prone to inter-/intra-observer errors. Recently, automated statistical imaging analysis techniques have been proposed to detect and segment MS lesions based on MRI voxel intensity. However, their effectiveness is limited by the heterogeneity of both MRI data acquisition techniques and the appearance of MS lesions. By learning complex lesion representations directly from images, deep learning techniques have achieved remarkable breakthroughs in the MS lesion segmentation task. Here, we provide a comprehensive review of state-of-the-art automatic statistical and deep-learning MS segmentation methods and discuss current and future clinical applications. Further, we review technical strategies, such as domain adaptation, to enhance MS lesion segmentation in real-world clinical settings.
- 16 February 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. 26 (6) , 2680-2692
Multiple Sclerosis Lesion Analysis in Brain Magnetic Resonance Images: Techniques and Clinical Applications
Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system, characterized by the appearance of focal lesions in the white and gray matter that topographically correlate with an individual patient’s neurological symptoms and signs. Magnetic resonance imaging (MRI) provides detailed in-vivo structural information, permitting the quantification and categorization of MS lesions that critically inform disease management. Traditionally, MS lesions have been manually annotated on 2D MRI slices, a process that is inefficient and prone to inter-/intra-observer errors. Recently, automated statistical imaging analysis techniques have been proposed to detect and segment MS lesions based on MRI voxel intensity. However, their effectiveness is limited by the heterogeneity of both MRI data acquisition techniques and the appearance of MS lesions. By learning complex lesion representations directly from images, deep learning techniques have achieved remarkable breakthroughs in the MS lesion segmentation task. Here, we provide a comprehensive review of state-of-the-art automatic statistical and deep-learning MS segmentation methods and discuss current and future clinical applications. Further, we review technical strategies, such as domain adaptation, to enhance MS lesion segmentation in real-world clinical settings.
- 21 September 2021
- Published by Springer Nature
- p. 660-669
LG-Net: Lesion Gate Network for Multiple Sclerosis Lesion Inpainting
- 21 September 2021
- Published by Springer Nature
- p. 660-669
LG-Net: Lesion Gate Network for Multiple Sclerosis Lesion Inpainting
- 1 January 2020
- Vol. 34 (1) , 49-52
[Effectiveness of spirolactone on the treatment of laryngeal edema and complications after H-uvulopalatopharyngoplasty for patients with obstructive sleep apnea].
Objective:To determine whether taking spirolactone orally after H-UPPP may relieve laryngeal edema and complications for patients with obstructive sleep apnea(OSA). Method:Fifty patients with OSA to undergo H-UPPP operation were randomly divided equally to the intervention group(taking spirolactone 20 mg orally twice a day for 7 days after H-UPPP) or the control group, all patients received conventional therapy after H-UPPP including anti-infection, hemostatic treatment, fluid replacement and expectorant by fogged absorption. The pharyngeal wound, diet, sleep and speaking pronunciation of all patients in each group were evaluated every other day in 7 days postoperation. The minimum oxygen saturation of blood(SaO2) during sleep at night each day and the period needed for staphyledema resolution of all patients were recorded and compared between each group. Result:Postoperatively, the intervention group had significantly slighter bleeding at wound site, better sleep and more legible speaking pronunciation than the control group after 3 days to 5 days(PPPPP<0.05). Conclusion:Taking spirolactone orally after H-UPPP may relieve laryngeal edema and complications for OSA patients, and it will also shorten the period needed for staphyledema resolution.
- 1 January 2020
- Vol. 34 (1) , 49-52
[Effectiveness of spirolactone on the treatment of laryngeal edema and complications after H-uvulopalatopharyngoplasty for patients with obstructive sleep apnea].
Objective:To determine whether taking spirolactone orally after H-UPPP may relieve laryngeal edema and complications for patients with obstructive sleep apnea(OSA). Method:Fifty patients with OSA to undergo H-UPPP operation were randomly divided equally to the intervention group(taking spirolactone 20 mg orally twice a day for 7 days after H-UPPP) or the control group, all patients received conventional therapy after H-UPPP including anti-infection, hemostatic treatment, fluid replacement and expectorant by fogged absorption. The pharyngeal wound, diet, sleep and speaking pronunciation of all patients in each group were evaluated every other day in 7 days postoperation. The minimum oxygen saturation of blood(SaO2) during sleep at night each day and the period needed for staphyledema resolution of all patients were recorded and compared between each group. Result:Postoperatively, the intervention group had significantly slighter bleeding at wound site, better sleep and more legible speaking pronunciation than the control group after 3 days to 5 days(PPPPP<0.05). Conclusion:Taking spirolactone orally after H-UPPP may relieve laryngeal edema and complications for OSA patients, and it will also shorten the period needed for staphyledema resolution.